Last mentioned: Mar 11, 2026
Offering Upsized
The company prices an upsized $550M offering due to strong institutional interest.
ARK Invest Trade
Cathie Wood's ARK Invest buys the dip, increasing its position in CRSP shares.
Debt Offering Announced
CRISPR Therapeutics announces a $350M convertible senior notes offering, causing a stock price dip.
Cure Announcement
Medical officials formally announce the patient is cured, marking a global first for gene editing technology.
Six-Month Follow-up
Clinical evaluations confirm significant biological markers of recovery and the absence of off-target effects.
Therapy Administration
A one-time gene editing intervention is administered at a specialized pediatric facility in British Columbia.
Trial Enrollment
The B.C. teen is enrolled in a world-first experimental gene editing clinical trial for a rare genetic disorder.
ARK Invest founder Cathie Wood has increased her stake in CRISPR Therapeutics following a stock price decline triggered by a significant convertible debt offering. The move underscores Wood's long-term conviction in the gene-editing sector despite short-term market volatility and capital-raising pressures.
ARK Invest, led by Cathie Wood, has significantly increased its position in CRISPR Therapeutics (CRSP), signaling continued high conviction in the gene-editing pioneer despite recent market fluctuations. This move highlights Wood's strategy of doubling down on disruptive genomic technologies during periods of valuation compression.
A British Columbia teenager has achieved a historic medical milestone, becoming the first person globally to be cured of a rare genetic disease using advanced gene editing technology. This breakthrough marks a definitive shift in the treatment of rare disorders, moving from chronic management to a potential one-time curative intervention.